Australia Vaccine Market Size & Outlook, 2023-2030
Australia vaccine market, 2018-2030 (US$M)
Related Markets
Australia vaccine market highlights
- The Australia vaccine market generated a revenue of USD 1,858.4 million in 2023 and is expected to reach USD 2,014.8 million by 2030.
- The Australia market is expected to grow at a CAGR of 1.2% from 2024 to 2030.
- In terms of segment, subunit vaccines was the largest revenue generating type in 2023.
- Subunit Vaccines is the most lucrative type segment registering the fastest growth during the forecast period.
Vaccine market data book summary
| Market revenue in 2023 | USD 1,858.4 million |
| Market revenue in 2030 | USD 2,014.8 million |
| Growth rate | 1.2% (CAGR from 2023 to 2030) |
| Largest segment | Subunit vaccines |
| Fastest growing segment | Subunit Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Subunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
Other key industry trends
- In terms of revenue, Australia accounted for 2.4% of the global vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China vaccine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,363.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Market Scope
Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Subunit vaccines was the largest segment with a revenue share of 34.12% in 2023. Horizon Databook has segmented the Australia vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The favorable regulatory framework and high demand for influenza vaccines in the country are likely to boost market growth. For instance, in March 2022, Seqirus announced that its Flucelvax Quad (quadrivalent influenza vaccine) was approved by the Therapeutic Goods Administration (TGA) for children aged 2 years and older.
This was the first one-cell-based flu vaccine in the country. Furthermore, positive trial results of vaccine candidates are likely to provide momentum to the country’s market growth. For instance, in April 2022, Novavax published clinical data for the combined flu and COVID-19 vaccine, with promising outcomes. This trial was conducted in Australia.
Vaccination is strongly recommended for people at highest risk; for instance, children under 2 years, people aged 15 to 19, and international travelers. Earlier, the meningococcal ACWY vaccine was funded by NIP for infants aged 12 months and above. In 2019, it was funded for 10-year-olds through a school program. Moreover, increasing introduction of novel meningococcal vaccines in the country will drive market growth.
Reasons to subscribe to Australia vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia vaccine market databook
-
Our clientele includes a mix of vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Australia vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia vaccine market size, by type, 2018-2030 (US$M)
Australia Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
